PrecisionLife and Ono Pharmaceutical have agreed a multi-target discovery and validation partnership.
The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono.
PrecisionLife analyses multi-modal datasets including genomic, clinical, and epidemiological data to accurately stratify patients and understand subgroup-relevant disease risks and drivers.
These insights are used to discover therapeutic targets for unmet medical needs, biomarkers to select the right patients for more targeted clinical trials, retrospective analysis of clinical trials, generation of clinical risk scores, and identification of indication extension opportunities.
Under the agreement, PrecisionLife will provide Ono with a clear rationale for selection of targets with genetic validation and mechanistic hypotheses, preclinical validation, and patient stratification biomarkers to optimise clinical development of the assets.
Ono will select targets from PrecisionLife’s recommendations and acquire the worldwide rights to develop and commercialise a pharmaceutical product acting on the target.
